WEDNESDAY 5 JUNE 13:30 – 17:30



ECFS European CF Pharmacy Group meeting Glasgow 2024

- 13:30 13:40 Welcome and introductions Maarten Ploeger, The Hague, NL
- 13:40 14:40 Introduction, context and background of the 6 selected objectives in the treatment of CF and the use of CFTR modulators H (Harry) Heijerman, Utrecht, NL
- 14:40 15:30 **Retrospective analysis of serum values of ETI in adult patients with CF** S (Susanne) Nährig, Munich, DE
- 15:30– 15:45 BREAK
- 15:45 16:30 Workgroup Sessions

A. Establishing Effective Strategies for preventing of liver-related side effects of CFTR modulators

B. Investigating drug-drug interactions associated with CFTR-modulators

C. Developing policies to address and manage psychological side effects of CFTR modulators

D. Early and late skin disorders after the use of CFTR modulators

E. Formulating long-term treatment strategies, including CVRM, Osteopenia/Osteoporosis, Diabetes

F. Developing a pharmacokinetic model/guideline in order to go to personalized dosing of CFTR modulators

- 16:30 17:15Feedback Workgroups and Wrap-up
Maarten Ploeger, The Hague, NL
- 17:15–17:30 Update Education Committee and Drug Dosing App Nicola Shaw, London, UK

Let us know if you plan to attend – email us: <u>ecfpg@outlook.com</u> or join the meeting via X: @ecfpg

To join, or learn more about the European CF Pharmacy Group, visit our web-page: <u>https://www.ecfs.eu/projects/european-cf-pharmacy-group/introduction</u>